Brave Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Brave Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,523	Closed	-$210K	–	162
2023 Q1	$210K	Sell	1,523 -977	-39%	-$127K	0.07%	122
2022 Q4	$324K	Hold	2,500	–	–	0.11%	89
2022 Q3	$276K	Sell	2,500 -1,175	-32%	-$118K	0.14%	90
2022 Q2	$275K	Sell	3,675 -475	-11%	-$34.9K	0.12%	98
2022 Q1	$324K	Hold	4,150	–	–	0.11%	95
2021 Q4	$374K	Hold	4,150	–	–	0.1%	86
2021 Q3	$384K	Buy	+4,150	New	+$320K	0.11%	87
2021 Q2	–	Sell	-3,125	Closed	-$233K	–	165
2021 Q1	$233K	Buy	+3,125	New	+$288K	0.08%	120

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brave Asset Management's SRPT Position: Q2 2023 in Review

Brave Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 1,523 shares — an estimated $210K sold.

Brave Asset Management first reported a position in SRPT in Q1 2021 and held it in 8 quarters. The position peaked at $384K in Q3 2021. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Brave Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Brave Asset Management sold 1,523 Sarepta Therapeutics shares in Q2 2023, an estimated $210K.
Brave Asset Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 8 quarters.
Brave Asset Management's Sarepta Therapeutics position peaked at $384K in Q3 2021.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Brave Asset Management's 13F filing for Q2 2023, filed 24 Jul 2023.